Compare MTEX & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTEX | ICCM |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.3M |
| IPO Year | 1998 | 2013 |
| Metric | MTEX | ICCM |
|---|---|---|
| Price | $8.54 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.67 |
| AVG Volume (30 Days) | 26.9K | ★ 167.5K |
| Earning Date | 11-11-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $108,038,000.00 | N/A |
| Revenue This Year | N/A | $27.11 |
| Revenue Next Year | N/A | $104.97 |
| P/E Ratio | $8.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.80 | $0.13 |
| 52 Week High | $12.45 | $9.54 |
| Indicator | MTEX | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 21.20 |
| Support Level | $6.60 | $0.96 |
| Resistance Level | $9.58 | $2.50 |
| Average True Range (ATR) | 0.64 | 0.13 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 79.26 | 9.29 |
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.